Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2025)
Syndax Pharmaceuticals (SNDX) posted quarterly Operating Leases of $1.5 million for Q4 2025, down 3.61% year-over-year from $1.6 million in Q4 2024, and down 3.61% quarter-over-quarter from $1.6 million in Q4 2024.
Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2025) Analysis & Trends
Syndax Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $1.5 million for Q4 2025.
- In Q4 2025, Operating Leases fell 3.61% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (down 3.61% YoY), while the FY2025 annual figure was $1.5 million, down 3.61% from the prior year.
- Operating Leases for Q4 2025 stood at $1.5 million, down from $1.6 million in the prior quarter.
- The five-year high for Operating Leases was $1.6 million in Q4 2024, with the low at $22000.0 in Q2 2021.
- The 5-year median for Operating Leases is $676000.0 (2022), against an average of $685750.0.
- The sharpest annual moves came in 2021 and 2022: Operating Leases sank 90.83% in 2021, then soared 2490.91% in 2022.
- Syndax Pharmaceuticals' Operating Leases stood at $711000.0 in 2021, then decreased by 0.28% to $709000.0 in 2022, then decreased by 18.48% to $578000.0 in 2023, then jumped by 173.01% to $1.6 million in 2024, then decreased by 3.61% to $1.5 million in 2025.
- Business Quant data shows SNDX's Operating Leases at $1.5 million in Q4 2025, $1.6 million in Q4 2024, and $133000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Jun 30, 2024 | 133,000.00 |
| Mar 31, 2024 | 327,000.00 |
| Dec 31, 2023 | 578,000.00 |
| Sep 30, 2023 | 851,000.00 |
| Jun 30, 2023 | 1.12 Mn |
| Mar 31, 2023 | 588,000.00 |
| Dec 31, 2022 | 709,000.00 |
| Sep 30, 2022 | 768,000.00 |
| Jun 30, 2022 | 570,000.00 |
| Mar 31, 2022 | 643,000.00 |
| Dec 31, 2021 | 711,000.00 |
| Sep 30, 2021 | 798,000.00 |
| Jun 30, 2021 | 22,000.00 |
| Mar 31, 2021 | 60,000.00 |
| Dec 31, 2020 | 101,000.00 |
| Sep 30, 2020 | 172,000.00 |
| Jun 30, 2020 | 240,000.00 |
| Mar 31, 2020 | 306,000.00 |